162 related articles for article (PubMed ID: 29248575)
1. Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
Natale A; Boeckmans J; Desmae T; De Boe V; De Kock J; Vanhaecke T; Rogiers V; Rodrigues RM
Toxicol Lett; 2018 Mar; 284():184-194. PubMed ID: 29248575
[TBL] [Abstract][Full Text] [Related]
2. High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
van de Water FM; Havinga J; Ravesloot WT; Horbach GJ; Schoonen WG
Toxicol In Vitro; 2011 Dec; 25(8):1870-82. PubMed ID: 21651975
[TBL] [Abstract][Full Text] [Related]
3. Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment.
Bocchini N; Giantin M; Crivellente F; Ferraresso S; Faustinelli I; Dacasto M; Cristofori P
J Appl Toxicol; 2015 Jan; 35(1):90-103. PubMed ID: 25580480
[TBL] [Abstract][Full Text] [Related]
4. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
Sawada H; Takami K; Asahi S
Toxicol Sci; 2005 Feb; 83(2):282-92. PubMed ID: 15342952
[TBL] [Abstract][Full Text] [Related]
5. Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver.
Sanoh S; Yamachika Y; Tamura Y; Kotake Y; Yoshizane Y; Ishida Y; Tateno C; Ohta S
J Toxicol Sci; 2017; 42(5):589-596. PubMed ID: 28904294
[TBL] [Abstract][Full Text] [Related]
6. In vitro assays and biomarkers for drug-induced phospholipidosis.
Monteith DK; Morgan RE; Halstead B
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
[TBL] [Abstract][Full Text] [Related]
7. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development.
Casartelli A; Bonato M; Cristofori P; Crivellente F; Dal Negro G; Masotto I; Mutinelli C; Valko K; Bonfante V
Cell Biol Toxicol; 2003 Jun; 19(3):161-76. PubMed ID: 12945744
[TBL] [Abstract][Full Text] [Related]
8. From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier.
Yang L; Zhong X; Li Q; Zhang X; Wang Y; Yang K; Zhang LW
Toxicol Sci; 2017 Mar; 156(1):39-53. PubMed ID: 28013220
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced phospholipidosis: are there functional consequences?
Reasor MJ; Kacew S
Exp Biol Med (Maywood); 2001 Oct; 226(9):825-30. PubMed ID: 11568304
[TBL] [Abstract][Full Text] [Related]
10. In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells.
Rodrigues RM; Branson S; De Boe V; Sachinidis A; Rogiers V; De Kock J; Vanhaecke T
Arch Toxicol; 2016 Mar; 90(3):677-89. PubMed ID: 25716160
[TBL] [Abstract][Full Text] [Related]
11. Influence of a pre-existing phospholipidosis on the accumulation of amiodarone and desethylamiodarone in rat alveolar macrophages.
Reasor MJ
Res Commun Chem Pathol Pharmacol; 1991 May; 72(2):169-81. PubMed ID: 1876748
[TBL] [Abstract][Full Text] [Related]
12. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
13. Predicting the Risk of Phospholipidosis with in Silico Models and an Image-Based in Vitro Screen.
Fusani L; Brown M; Chen H; Ahlberg E; Noeske T
Mol Pharm; 2017 Dec; 14(12):4346-4352. PubMed ID: 29077420
[TBL] [Abstract][Full Text] [Related]
14. Human skin-derived stem cells as a novel cell source for in vitro hepatotoxicity screening of pharmaceuticals.
Rodrigues RM; De Kock J; Branson S; Vinken M; Meganathan K; Chaudhari U; Sachinidis A; Govaere O; Roskams T; De Boe V; Vanhaecke T; Rogiers V
Stem Cells Dev; 2014 Jan; 23(1):44-55. PubMed ID: 23952781
[TBL] [Abstract][Full Text] [Related]
15. Hydrophilic interaction chromatography with a focus on the drug-phosphate interaction in drug screening to determine the phospholipidosis induction risk.
Okamoto H; Hamaguchi R; Kuroda Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Apr; 1051():33-40. PubMed ID: 28285021
[TBL] [Abstract][Full Text] [Related]
16. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.
Shahane SA; Huang R; Gerhold D; Baxa U; Austin CP; Xia M
J Biomol Screen; 2014 Jan; 19(1):66-76. PubMed ID: 24003057
[TBL] [Abstract][Full Text] [Related]
17. Increased hepatic density and phospholipidosis due to amiodarone.
Goldman IS; Winkler ML; Raper SE; Barker ME; Keung E; Goldberg HI; Boyer TD
AJR Am J Roentgenol; 1985 Mar; 144(3):541-6. PubMed ID: 3871563
[TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages.
McCloud CM; Beard TL; Kacew S; Reasor MJ
Exp Mol Pathol; 1995 Feb; 62(1):12-21. PubMed ID: 7556587
[TBL] [Abstract][Full Text] [Related]
19. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines.
Ploemen JP; Kelder J; Hafmans T; van de Sandt H; van Burgsteden JA; Saleminki PJ; van Esch E
Exp Toxicol Pathol; 2004 Mar; 55(5):347-55. PubMed ID: 15088636
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis by cationic amphiphilic drugs amiodarone and imipramine.
Piccotti JR; LaGattuta MS; Knight SA; Gonzales AJ; Bleavins MR
Drug Chem Toxicol; 2005; 28(1):117-33. PubMed ID: 15720040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
